• Royalty Pharma plc (NasdaqGS:RPRX) was added to both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index on 27 June 2026, highlighting its classification among larger, relatively more defensive US equities.
• This dual index inclusion can raise Royalty Pharma’s visibility with institutional investors and index-tracking funds, potentially increasing demand for its shares and reinforcing its profile as a defensive healthcare royalty specialist.
• Next, we’ll examine how joining the Russell 1000 Defensive family may influence Royalty Pharma’s investment narrative and perceived risk-return profile.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Royalty Pharma Investment Narrative Recap

To own Royalty Pharma, you need to believe in its role as a diversified “royalty bank” on innovative drugs, with cash flows that can be reinvested into new deals and returned to shareholders. The Russell 1000 Defensive index additions reinforce its defensive label but do not materially change the near term focus on resolving the Alyftrek royalty dispute and managing competition for attractive royalty assets.

Against this backdrop, the new US$1.8 billion revolving credit facility stands out. It extends liquidity through 2031 and modestly increases borrowing capacity, which can support future royalty acquisitions and share buybacks. That financial flexibility could matter for the next phase of deal activity, even as investors weigh regulatory risks, competition, and concentration in a handful of key royalty streams.

Yet while the index additions highlight stability, investors should also be aware of how concentrated royalty exposure can quickly turn if...

Royalty Pharma's narrative projects $4.3 billion revenue and $3.2 billion earnings by 2029. This requires 20.9% yearly revenue growth and an earnings increase of about $2.4 billion from $826.3 million today.

Uncover how Royalty Pharma's forecasts yield a $59.25 fair value, in line with its current price.

Exploring Other Perspectives

While the Russell inclusion suggests resilience, remember some of the lowest analysts already assumed earnings of about US$3.2 billion by 2029, yet still worried that rising interest costs could erode returns and make today’s rich margins harder to sustain.

Explore 5 other fair value estimates on Royalty Pharma - why the stock might be worth 17% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Royalty Pharma research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Royalty Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Royalty Pharma's overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.